Inclusion Criteria:

- Female patients, >/= 18 years of age

- Metastatic breast cancer

- Estrogen receptor- , progesterone- and HER2-negative disease

- Treatment-naïve for metastatic breast cancer

- Eastern Cooperative Oncology Group (ECOG) performance status 0-1

- Adequate hematological, renal and liver function

Exclusion Criteria:

- Prior first line treatment for metastatic breast cancer

- CNS metastasis

- Uncontrolled hypertension (> 170/95 mmHg)

- Evidence of bleeding diathesis, coagulopathy or hemorrhage at baseline

- History of other malignant disease within past 3 years, except for curatively treated
basal cell carcinoma of the skin and carcinoma in situ of the cervix

- Prior therapy with gemcitabine or carboplatin in the metastatic setting. Patients
having received gemcitabine or carboplatin as part of adjuvant therapy are eligible,
if recurrence was first documented >6 months after the last exposure to the drug(s)

- Requirement of chronic use of immunosuppressive agents

- HIV, hepatitis B or hepatitis C infection